Note: This article was originally published by Hospital News on February 25, 2021 featuring world-class chemist and Singletto advisor Dr. Belinda Heyne on the perpetual decontamination ability of Light-Activated Dyes..

Original Link

A new, safe, and affordable SARS-CoV-2 decontamination method has been identified and is now being commercially tested and developed for masks and Personal Protective Equipment (PPE). This method works perpetually, even while a mask is being worn.

This novel decontamination method relies solely on protective dyes, indoor light, and ever-present oxygen.

The DeMaND study co-authored by 52 researchers worldwide with support from 13 labs and institutions, including the WHO, AHS, CDC, University of Calgary, University of Alberta, Québec-Université Laval, Stanford, and the University of Washington, was recently pre-published. For the first time, Methylene Blue (MB), a Light-Activated Dye was shown to inactivate SARS-CoV-2 on a variety of commonly used masks while keeping their integrity.

This Light-Activated Dye, when applied to coronavirus-infected masks, consistently decontaminated SARS-CoV-2 from the masks within 30 minutes and in many cases in less than five minutes.

Further, masks pre-treated with Methylene Blue provided ongoing decontamination once exposed to SARS-CoV-2.

Continue reading on


November 15, 2021
Protective Dye Methylene Blue Plus Light Proven to Inactivate "Hard-to-kill" Norovirus

Singletto's Dr. Lendvay contributed to a New MB Study


May 22, 2021
Infection Control & Hospital Epidemiology Publishes Drs. Lendvay, Chen, et al. WHO-led DeMaND Study

The Infection Control & Hospital Epidemiology medical journal has published the peer-reviewed DeMaND study. Singletto’s Dr. Tom Lendvay served as Lead Author.


May 20, 2021
Top Doctor 2021: Singletto’s Lendvay Named by Seattle Magazine

Dr. Thomas Lendvay, Singletto’s Co-Founder and Chief Medical Officer was just named a “Top Doctor” by Seattle Magazine.


March 25, 2021
A Moral Obligation: Why the Former Providence President Wants Singletto Tech Out Now

Mike Butler spent over two decades in leadership at Providence Health, growing such from a $2 billion organization to $25 billion. Upon recently retiring, Mike knew he wanted to find ways to continue impacting the lives and health of others. Now at Singletto, Mike is on a mission to bring the novel Singletto technology to market – in healthcare and beyond. But, it’s not just a passion project … upon learning about the technology, Mike felt a moral obligation to get it in as many hands as possible. More with recently retired Providence Health President Mike Butler…


February 25, 2021
Hospital News: Light kills. SARS-CoV-2, That Is.

Singletto Advisor Dr. Belinda Heyne shares DeMaND study results on Hospital News.

Lacey Duffy

Customer Experience
February 12, 2021
CBC: This simple mix of dye and light could decontaminate masks for reuse

Dr. Belinda Heyne was recently featured in a CBC piece covering the DeMaND study’s findings and the life-giving potential of dye and light.